New Products

Premium

Intrinsic Bioprobes this week launched three assays for protein biomarkers tied to kidney disease and renal failure.

The assays, which are based on the company's Mass Spectrometric Immunoassay technology, quantitate levels of beta-2-microglobulin, cystatin C, and retinol binding protein, which, the company said, are FDA-approved clinical markers for kidney disease and renal failure.

The assays will be offered out of the CLIA-certified diagnostic laboratory of the Institute for Genomics Medicine at the University of Medicine and Dentistry of New Jersey.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.